One-Time gene injection aims to halt rare blindness
NCT ID NCT07653971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a single injection of a gene therapy called ZVS101e for people with Bietti crystalline dystrophy, a rare inherited eye disease that leads to progressive vision loss. The therapy uses a harmless virus to deliver a working copy of the CYP4V2 gene to cells in the eye. Participants receive one injection in the study eye and are followed for 4 weeks to check safety and early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZVS101e (a gene therapy injection using a harmless virus to deliver a working copy of the CYP4V2 gene)
What this could lead to
If successful, this could provide a treatment option for people with Bietti crystalline dystrophy, potentially slowing vision loss or improving sight.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not apply to everyone. Gene therapy carries risks like inflammation or retinal damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boao Super Hospital
Qionghai, Hainan, China
-
Hainan Boao Ophthalmology Center, Zhongshan Ophthalmic Center, Sun Yat-sen University
Qionghai, Hainan, China